The IV iron market by nephrology is increasing at a faster rate due to the increasing prevalence of chronic kidney diseases (CKD) globally.
Arizton’s recent market research report on the oral and IV iron market provides a comprehensive industry study, competitive analysis, and trend forecasts. The research study segments the market by route of administration (oral iron drugs and intravenous iron drugs), application (nephrology, OBGYN, surgeries, gastroenterology, oncology, and chronic heart failure), and geography (North America, Europe, APAC, and ROW). Vifor Pharma Group and Daiichi Sankyo Company are the key players in the global oral and IV iron market.
The global oral and IV iron market is anticipated to reach revenues of over $7.5 billion, growing at a CAGR of over 10% during 2018−2024.
As Iron is an essential for smooth functioning of multiple metabolic processes, including DNA synthesis, oxygen transport, and electron transport, its inadequate quantity in the human body can lead to iron deficiency (ID), which can affect several mechanisms, including reduction in the production of RBCs, thereby affecting transport of oxygen to different parts of the body. ID is the most prevalent single deficiency condition affecting children, men, and women.
The global oral and IV iron market is divided into three major segments- route of administration, application, and geography.
The IV iron drugs segment is expected to witness the highest incremental growth in the oral and IV iron market by ROA
The IV iron drugs segment is expected to witness growth at a higher pace than oral iron drugs as the uptake of IV iron drugs is increasing at a healthy rate, especially in developed economies. This segment is likely to experience an incremental growth of over $2.5 billion during the forecast period. The increasing need to treat iron deficiency in chronic disease patients, the increasing pool of patients with the high rate of unresponsive oral therapy, the rising global medicine and healthcare expenditure and high-sensitivity, accuracy, easy, and convenient access of intravenous iron dosages are expected to drive demand for the IV iron market by 2022. ViforPharma Group, Daiichi Sankyo Group, AMAG Pharmaceuticals, Sanofi, Pharmacosmos are the leading players offering branded IV iron drugs globally.
The Nephrology segment to grow at a lucrative CAGR during the forecast period
In 2018, the nephrology segment accounted for a share of 55% in the global oral and IV iron market. The iron drugs market by nephrology is increasing at a faster rate and is likely to continue at a similar pace due to the increasing prevalence of chronic kidney diseases (CKD) globally. The prevalence of iron deficiency is approximately 70% in patients with CKD. The nephrology segment is likely to grow at a higher CAGR of over 12% due to the successful clinically proven IV drugs for the treatment of ID and IDA.
The IV iron market has witnessed new iron formulations such as iron sucrose, which is replacing the usage of high molecular weight iron dextran, especially in dialysis patients. Several iron drugs were majorly approved for the treatment of iron deficiency in CKD patients due to the availability of abundant clinical data regarding safety and efficacy of iron drugs for treating ID in CKD patients.
The US accounts for the highest share of the North American oral and IV iron market
In 2018, North America was the largest market for intravenous and oral iron drugs worldwide, accounting for a market share of over 35%. The presence of a large proportion of the population with ID, coupled with better treatment access to ID and IDA, especially branded drugs, is the primary factor for its high market share. According to the United States Renal Data System (USRDS), the prevalence of CKD in the US alone was around 15%, which indicates around 30 million people affected by the disease.
An increased stressful lifestyle and the rise in chronic conditions are major reasons for the increase in the number of ID patient in the region. The US alone accounted for a share of 95% of the oral and IV iron market in North America. The market is growing due to the high uptake of expensive IV iron therapies over low-cost oral iron therapies. In 2018, the ViforPharma Group’s Venofer generated around $350 million in revenue in the US due to the high uptake of branded drugs.
AMAG Pharmaceuticals, Akebia Therapeutics, Shield Therapeutics, Pharmacosmos, Allergan, Sanofi, and AOP Orphan Pharmaceuticals are the other prominent vendors in the oral and IV iron market. A few other vendors in the market are Pfizer, Sunny Pharmaceutical, MEDICE, AZAD Pharma, Cirondrugs, and SalveoLifecare.
The complete overview of the latest market research report on the global oral and IV iron market by Arizton is now available.
The report offers a detailed study of major trends, drivers, challenges, and provides market sizing and forecast for major geographical regions and key countries.
Arizton – Advisory and Intelligence is an innovation and quality-driven firm, which offers cutting-edge research solutions to clients across the world. We excel in providing comprehensive market intelligence reports and advisory and consulting services.
We offer comprehensive market research reports on industries such as consumer goods and retail technology, automotive and mobility, smart tech, healthcare, and life sciences, industrial machinery, chemicals and materials, IT and media, logistics and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts.
Arizton comprises a team of exuberant and well-experienced analysts who have mastered in generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.
+1 302 469 0707